The initiation of coverage by Barclays with an Equal-Weight rating suggests a neutral outlook for the stock. The price target of $15 provides a reference point for investors, but does not necessarily imply a significant change in the stock's current price. Therefore, the short-term impact on the stock price is likely to be neutral.